Mallia Therapeutics

Mallia Therapeutics is a private, pre-clinical stage biotech leveraging a deep scientific foundation in immunology to develop novel regenerative therapies. Its platform centers on the MAL-856 molecule, a recombinant protein related to soluble sCD83, which is believed to resolve inflammation and activate tissue repair. The company is initially targeting significant unmet needs in alopecia, chronic wounds, and inflammatory skin disorders through a first-in-class mechanism. Operating as a virtual or highly collaborative entity, it advances its programs via a network of academic and industrial partners.

Platform based on soluble CD83 (sCD83) immunomodulation. Utilizes recombinant MAL-856 protein designed to mimic natural sCD83, a key mediator that resolves inflammation and activates tissue regeneration processes.

In alopecia, competition includes approved JAK inhibitors (e.g., baricitinib, ritlecitinib) and numerous clinical-stage candidates. The wound healing space has multiple growth factor and cell therapy approaches. The inflammatory skin disease market is dominated by targeted biologics (e.g., anti-IL-17, -IL-23). Mallia's differentiation lies in its novel resolution-of-inflammation mechanism.